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ABSTRACT
Objectives To identify overall disease course, 
progression patterns and risk factors predictive for 
progressive interstitial lung disease (ILD) in patients with 
systemic sclerosis- associated ILD (SSc- ILD), using data 
from the European Scleroderma Trials And Research 
(EUSTAR) database over long- term follow- up.
Methods Eligible patients with SSc- ILD were registered 
in the EUSTAR database and had measurements of 
forced vital capacity (FVC) at baseline and after 12±3 
months. Long- term progressive ILD and progression 
patterns were assessed in patients with multiple FVC 
measurements. Potential predictors of ILD progression 
were analysed using multivariable mixed- effect models.
Results 826 patients with SSc- ILD were included. Over 
12±3 months, 219 (27%) showed progressive ILD: 
either moderate (FVC decline 5% to 10%) or significant 
(FVC decline >10%). A total of 535 (65%) patients had 
multiple FVC measurements available over mean 5- year 
follow- up. In each 12- month period, 23% to 27% of 
SSc- ILD patients showed progressive ILD, but only a 
minority of patients showed progression in consecutive 
periods. Most patients with progressive ILD (58%) had a 
pattern of slow lung function decline, with more periods 
of stability/improvement than decline, whereas only 8% 
showed rapid, continuously declining FVC; 178 (33%) 
experienced no episode of FVC decline. The strongest 
predictive factors for FVC decline over 5 years were 
male sex, higher modified Rodnan skin score and reflux/
dysphagia symptoms.
Conclusion SSc- ILD shows a heterogeneous and 
variable disease course, and thus monitoring all patients 
closely is important. Novel treatment concepts, with 
treatment initiation before FVC decline occurs, should 
aim for prevention of progression to avoid irreversible 
organ damage.
INTRODUCTION
Systemic sclerosis (SSc) is a rare autoimmune 
disease, frequently complicated by interstitial 
lung disease (ILD), which is associated with worse 
outcomes.1–5 Some patients with SSc- associated 
ILD (SSc- ILD) develop progressive ILD, showing 
decline in lung function and/or increasing extent 
of fibrosis by high- resolution CT (HRCT).4–10 The 
proportion of patients with SSc- ILD who develop 
progressive ILD and the pattern of disease course 
in these patients are incompletely understood. Prior 
Key messages
What is already known about this subject?
 ► A subset of patients with systemic sclerosis- 
associated interstitial lung disease (SSc- ILD) 
develop progressive ILD, which is associated 
with higher mortality, but the prevalence of 
progressive ILD and the overall disease course 
and patterns of SSc- ILD are unknown. Current 
clinical practice emphasises treatment initiation 
of SSc- ILD patients with progressive ILD.
What does this study add?
 ► Around 30% of SSc- ILD patients experienced 
ILD progression during any 12- month period, 
and 67% of all SSc- ILD patients experienced 
progression at any time over the mean 5- year 
follow- up.
 ► ILD patterns in patients with SSc- ILD are very 
heterogeneous, with most patients showing 
both progressive and stable periods.
 ► Of all progressive SSc- ILD patients, only 
a minority showed a pattern of rapid, 
continuously declining forced vital capacity 
(FVC) with several consecutive episodes of 
FVC decline and no periods of FVC stability or 
improvement.
How might this impact on clinical practice or 
future developments?
 ► These results highlight a pitfall in current 
clinical practice, where treatment is often 
initiated after FVC decline has happened, and 
thus when lung damage has already occurred. 
Novel treatment concepts are needed and 
should aim for prevention of progression to 
avoid irreversible organ damage. This study 
defines factors that can identify patients at 
risk for progression. The results also stress the 
heterogeneity and variability of the course of 
ILD in SSc, and highlight the need for close 
monitoring of all patients with SSc- ILD.
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Systemic sclerosis
analyses of disease course in SSc- ILD have found different disease 
patterns in different patient cohorts.8–11 However, these studies 
are limited by their small sample size, selected patient popula-
tions, significant referral biases and statistical instabilities of the 
trajectories. Randomised clinical trials provide valuable data, 
but the 12- month or 24- month duration often used12–14 is insuf-
ficient for assessment of long- term disease course. There also 
remains a high unmet need to specifically identify patients with 
SSc at risk of progressive ILD. Risk factors for SSc- ILD progres-
sion have been proposed by several studies;15–21 however, their 
clinical applicability and specific power to predict progression 
are limited. The optimal combination of risk factors to accu-
rately predict progression has not been identified.
Treatments are available for SSc- ILD, but to date, nintedanib 
is the only approved treatment shown to reduce lung function 
decline in patients with SSc- ILD.14 22 23 Current clinical prac-
tice emphasises treatment of patients with progressive ILD,24 
and a recent study showed that nintedanib reduces decline of 
forced vital capacity (FVC) in progressive ILD associated with 
various underlying conditions, including connective tissue 
disease- associated ILD.25 However, waiting for FVC decline and/
or extensive ILD involvement neglects the opportunity of early 
Table 1 Overall baseline demographic and clinical characteristics of all patients with SSc- ILD and characteristics stratified by ILD progression over 
the 12±3- month observation period
Progression criteria: ∆FVC% predicted
Total
(N=826)
Significant progression 
(n=100)
Moderate progression 
(n=123)
Stable
(n=396)
Improvement 
(n=207)
<−10 −10 to −5 >−5 to <5 ≥5
Age, years (SD)* 56 (13.1) 59 (13.1) 56 (12.4) 55 (13.5) 58 (12.4)
Male, n (%)* 150 (18) 17 (17) 16 (13) 81 (20) 36 (17)
Disease characteristics at baseline
  Disease duration, years* (SD) 9.7 (8.3) 8.8 (7.7) 10.2 (8.2) 10.2 (8.5) 8.9 (8.3)
  Disease duration
  <3 years*, n (%)
175 (21) 26 (26) 27 (22) 68 (17) 54 (26)
  Diffuse cutaneous SSc, n (%) 365/732 (50) 44/96 (46) 55/106 (52) 182/357 (51) 84/173 (49)
  Limited cutaneous SSc, n (%) 367/732 (50) 52/96 (54) 51/106 (48) 175/357 (49) 89/173 (51)
  Anti- topoisomerase I Ab, n (%) 421/789 (53) 41/97 (42) 64/117 (55) 218/378 (58) 98/197 (50)
  Anti- centromere Ab, n (%) 141/783 (18) 19/97 (20) 18/113 (16) 59/376 (16) 45/197 (23)
  Anti- RNA polymerase III Ab, n (%) 23/451 (5) 3/54 (6) 3/60 (5) 10/217 (5) 7/117 (3)
  Follow- up period, years*, mean (SD) 5.4 (2.0) 5.8 (1.4) 5.6 (2.0) 4.8 (3.2) 5.0 (3.2)
Lung characteristics
FVC% predicted,* mean (SD) 87 (21.1) 95 (23.3) 90 (21.8) 85 (20.4) 85 (19.7)
DLCO% predicted,* mean (SD) 59 (18.3) 61 (17.8) 60 (17.9) 58 (19.3) 60 (16.8)
∆FVC% predicted,† mean (SD) –0.1 (10.2) –18 (7.9) –7 (1.3) 0.3 (2.2) 12 (7.0)
∆DLCO% predicted,† mean (SD) –0.7 (12.2) –4 (15.4) 2 (12.8) –0.3 (10.9) 0.9 (11.9)
NYHA class, n (%) N=797 n=99 n=119 n=377 n=202
  1 363 (44) 44 (44) 57 (46) 167 (42) 95 (46)
  2 317 (38) 42 (42) 44 (36) 152 (38) 79 (38)
  3 103 (13) 10 (10) 17 (14) 50 (13) 26 (13)
  4 14 (2) 3 (3) 1 (1) 8 (2) 2 (1)
Other characteristics
mRSS, mean (SD) N=747
10 (8.1)
n=96
11 (7.6)
n=112
10 (8.5)
n=352
10 (7.6)
n=187
10 (8.8)
∆mRSS,† mean (SD) N=698
–0.4 (4.6)
n=88
0.5 (4.3)
n=103
–0.4 (3.1)
n=337
–0.3 (4.4)
n=170
–1.2 (5.6)
Reflux/dysphagia symptoms, n (%) 547/822 (67) 76/100 (76) 83/122 (68) 261/393 (66) 127/207 (61)
Digital ulcers, n (%) 266/808 (32) 35/100 (35) 38/118 (31) 141/386 (36) 5/2042 (25)
Tendon friction rubs, n (%) 73/804 (9) 7/99 (7) 10/119 (8) 35/383 (9) 21/203 (10)
Synovitis, n (%) 117/810 (14) 18/100 (18) 15/120 (13) 60/386 (16) 24/204 (12)
Muscle weakness, n (%) 182/814 (22) 25/100 (25) 31/120 (25) 78/388 (20) 48/206 (23)
Scleroderma renal crisis, n (%) 11/818 (1) 4/100 (4) 3/120 (2) 6/391 (2) 1/206 (0.5)
ESR, mean (SD) 766 (93)
26 (20.6)
98 (98)
29 (23.9)
115 (93)
25 (21.7)
361 (91)
26 (19.5)
192 (93)
25 (20.2)
Elevated CRP, n (%) 217/797 (27) 40/99 (30) 25/120 (33) 98/377 (26) 49/201 (24)
Immunosuppressant use, n (%) 89/244 (37) 8/20 (40) 8/31 (26) 51/121 (42) 22/72 (31)
Significant progression (FVC decline of >10%); moderate progression (FVC decline of 5% to 10%); stable ILD (FVC decline or improvement of <5%); moderate improvement 
(FVC improvement of 5% to 10%). Definitions of organ manifestations were described previously.3 28 All characteristics were assessed before or on the index date. The 
following treatment options were received by the included patients at baseline, and for this study were defined as immunosuppressive: prednisone >10 mg/day, azathioprine, 
cyclophosphamide, mycophenolate, methotrexate or rituximab.
*Available for all 826 patients.
†Change from baseline to 12 months.
Ab, antibody; CRP, C- reactive protein; DLCO, diffusion capacity of the lungs for carbon monoxide; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; mRSS, modified 
Rodnan skin score; NYHA, New York Heart Association; SSc, systemic sclerosis; SSc- ILD, systemic sclerosis- associated interstitial lung disease.
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treatment intervention until after clinically meaningful lung 
damage has occurred. Novel treatment concepts are therefore 
aiming to prevent progression and avoid irreversible damage 
to organs. This requires an understanding of the course and 
patterns of ILD progression, and reliable prediction algorithms 
that allow the specific detection of patients at risk of progression 
at a very early stage. Unfortunately, in SSc- ILD, this knowledge 
is currently lacking, and treatment initiation is often delayed in 
clinical practice by waiting for lung function decline over the 
preceding year before initiation.
The European Scleroderma Trials And Research (EUSTAR) 
group database is a large, real- world database representative of 
the general SSc population. It includes a wide range of patients 
with SSc- ILD, from those with mild and stable to advanced 
progressive disease.26 27
Thus, the aims of this study were: to assess the prevalence 
of progressive ILD over 12- month periods; to examine disease 
course and identify patterns of ILD progression in SSc over 
a 5- year period; and to identify risk factors predictive for 
progressive ILD in patients with SSc- ILD, using the EUSTAR 
database.
MATERIALS AND METHODS
Study design
Post hoc analyses of prospectively collected patient data from 
the EUSTAR database were conducted. The structure of the 
online database, the collected data set and definitions of clinical 
variables have been described in detail previously.3 28
Patient population and characteristics
Patients registered since 2010 in the EUSTAR database (start 
of the online version), aged ≥18 years, who fulfilled the 2013 
American College of Rheumatology/European League Against 
Rheumatism SSc classification criteria;29 30 with presence of ILD 
by HRCT or X- ray; recorded disease duration; and with avail-
able measurements of FVC and diffusion capacity of the lungs 
for carbon monoxide (DLCO) at baseline and after 12±3 months 
were included.
Progressive ILD measured by FVC changes in a 12-month 
period
To reflect clinical practice with respect to patient follow- up, 
and the usual study duration in clinical SSc- ILD trials, absolute 
changes in FVC% predicted were first evaluated over a 1- year 
period (baseline to 12±3 months).8 14 31 32 FVC decline ≥10% 
predicted is frequently used to define significant ILD progression 
and was therefore selected in this study as the main outcome 
measure for progressive ILD. Furthermore, an FVC decline 
>5% predicted is greater than the estimated minimum clinically 
important difference at a group level and has previously been 
associated with increased mortality in SSc.33 34 Patients were 
therefore divided into four progressive ILD subgroups based 
on absolute change in FVC% predicted from baseline to 12±3 
months: significant progression (decline of >10%); moderate 
progression (decline of 5% to 10%); stable ILD (decline or 
improvement of <5%); and improvement (improvement of 
≥5%) (table 1). The prevalence of annual FVC changes was 
assessed prospectively in patients with available data over a 
mean follow- up of 5 years, using the definitions of progressive 
ILD described above.
Progressive ILD measured by changes in FVC and DLCO over 12 
months
A decline in FVC of ≥10%, or a decline in FVC of 5% to 10% 
along with a decline in DLCO of 15%, is a proposed definition 
of progressive fibrosis.8 31 35 36 Therefore, we also assessed the 
prevalence of this combined endpoint.
Disease course and patterns in patients with SSc-ILD, 
measured by change in FVC from baseline to last available 
measurement
Because annual FVC patterns can change over time, we evalu-
ated the overall lung function course in patients who had at least 
two 12- month periods with FVC measurements. These periods 
could be, but did not need to be, consecutive. For the overall 
FVC course, patients were divided into five subgroups based on 
the difference between the first and last available FVC measure-
ment: major decline (FVC decline of >20%); significant decline 
(FVC decline of >10 and ≤20%); moderate decline (FVC 
decline of 5% to 10%); stable (FVC decline or improvement of 
<5%); and improvement (FVC improvement of ≥5%).
Figure 1 FVC changes among patients with SSc- ILD in the EUSTAR 
database (number of patients per category): (A) overall change during 
the 5- year follow- up period; (B) changes during each 12- month follow- 
up period. (A) Patients for whom ≥3 serial FVC measurements were 
available were divided into five disease course subgroups based on 
the overall difference between the first and last FVC measurement (% 
predicted): major decline (FVC decline of >20%); significant decline 
(FVC decline of >10% to 20%); moderate decline (FVC decline of 5% to 
10%); stable (FVC decline or improvement of <5%); and improvement 
(FVC improvement of ≥5%). (B) Disease course each year was evaluated 
by determining the magnitude of FVC changes (% predicted) in each 
12- month period during the mean 5- year follow- up defined as follows: 
significant decline (FVC decline of >10%); moderate decline (FVC 
decline of 5% to 10%); stable (FVC decline or improvement of <5%); 
and improvement (FVC improvement of ≥5%). EUSTAR, European 
Scleroderma Trials And Research; FVC, forced vital capacity; SSc- ILD, 
systemic sclerosis- associated interstitial lung disease.
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The numbers of patients who experienced no 12- month 
period of decline, one period of decline (moderate or significant) 
or multiple periods of decline (moderate, significant or both) 
across all periods with data available over the 5- year follow- up 
were assessed. Patients with ILD progression were split into 
different progression patterns according to the number of FVC 
decline periods: rapid progression (no periods of FVC stability 
or improvement); progression (more periods of decline than 
stability/improvement); and slow progression (more periods of 
stability/improvement than decline).
Mortality
All- cause mortality was assessed in all patients with SSc- ILD, and 
in patients with progressive ILD, until last available follow- up.
Risk factors predictive for progressive ILD
Candidate baseline variables to predict progressive ILD were 
selected based on reports from the published literature and 
expert opinion: sex,15 age,16 reflux/dysphagia symptoms,17 18 
SSc subtype,16 antibody status (anti- topoisomerase antibody 
(ATA) anti- centromere antibody (ACA), anti- RNA polymerase 
III antibody (ARA)),16 19 baseline FVC,16 20 baseline DLCO,
16 21 
disease duration,11 15 37 38 skin involvement measured by modi-
fied Rodnan skin score (mRSS),16 19 21 39 erythrocyte sedimenta-
tion rate (ESR), C- reactive protein (CRP) level, dyspnoea class, 
treatment, synovitis and muscle weakness.16 Extent of lung 
fibrosis on HRCT was not included due to extensive missing 
data.
Statistical methods
All analyses were performed using IBM SPSS Statistics V.25 and 
Stata V.15. Pearson χ2 test, Fisher’s exact test or independent 
sample t- test was used, as appropriate. For correlation analyses, 
Pearson or Kendall’s tau- b coefficients were applied as appro-
priate. All multivariable analyses were preceded by estimation of 
correlation between risk factors. Univariable and multivariable 
logistic regression analyses with OR and 95% CI were applied to 
analyse the predictive ability of baseline variables for progressive 
ILD. In the multivariable analyses, 10 events per variable were 
needed, and the variables were selected by expert opinion.
Univariable and multivariable linear mixed- effect models were 
performed to identify risk factors of longitudinal changes in 
FVC (% predicted) over the maximum 5- year follow- up period 
(baseline, 1, 2, 3, 4 and 5 years). Only patients with at least three 
serial FVC measurements were included in the analyses. Time 
and risk factors were fixed effects. Interaction effects between 
time and fixed factors were checked by including product terms 
in the models. Only significant interaction terms in the univari-
able analysis are presented, and they were further included in the 
multivariable model. Risk factors selected for multivariable anal-
yses were based on expert opinion. All models included random 
intercept and slope, and an unstructured correlation matrix was 
used.
Patient and public involvement
EUSTAR is part of the World Scleroderma Foundation, which 
has patient representatives from the Federation of European 
Scleroderma Associations (FESCA) in its governing board.
RESULTS
Patient population
Within the EUSTAR database, 6004 patients included since 2010 
aged ≥18 years fulfilled the SSc classification criteria and had 
lung imaging data available. Of these, 2259 (38%) had evidence 
of SSc- ILD on imaging, of which 826 had valid lung function 
data available after 12±3 months follow- up and were eligible 
for inclusion.
Demographic and clinical characteristics of all eligible patients 
are shown in table 1. No significant difference was observed in 
the baseline characteristics of the 826 eligible patients and the 
1433 ineligible patients (online supplementary table S1).
Prevalence and risk factors of progressive ILD at 12 months
When analysing the prevalence of progressive ILD within the 
initial 12- month period, we found that 100 patients (12%) had 
significant ILD progression, 123 (15%) had moderate progres-
sion, 396 (48%) were stable and 207 (25%) had improvement.
In multivariable logistic regression analyses, FVC (OR 1.02; 
95% CI 1.01 to 1.03; p<0.001), presence of reflux/dysphagia 
symptoms (OR 1.97; 95% CI 1.14 to 3.40; p=0.016) and mRSS 
(OR 1.06; 95% CI 1.00 to 1.12; p=0.036) at baseline were 
predictive for significant ILD progression at 12±3 months. No 
association was seen with age, sex, disease duration, antibody 
status, SSc subtype or immunosuppressant treatment.
Figure 2 FVC changes in consecutive 12- month periods among 
patients with SSc- ILD in the EUSTAR database (number of patients 
per category): (A) subsequent course among patients with stable or 
improved FVC during the first year of follow- up; (B) subsequent course 
among patients with minor or moderate decline during the first year 
of follow- up and those who had further declines. Disease course each 
year was evaluated by determining the magnitude of FVC changes 
(% predicted) in individual patients in each 12- month period during 
the mean 5- year follow- up, defined as follows: significant decline 
(FVC decline of >10%); moderate decline (FVC decline of 5% to 
10%); stable (FVC decline or improvement of <5%); and improvement 
(FVC improvement of ≥5%). EUSTAR, European Scleroderma Trials 
And Research; FVC, forced vital capacity; SSc- ILD, systemic sclerosis- 
associated interstitial lung disease.
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Prevalence and prediction of progressive ILD measured by the 
combined FVC and DLCO definition over the initial 12- month 
period were comparable to these data (online supplementary 
table S1 and figure S1).
Disease course and ILD patterns in patients with SSc-ILD
A total of 535 (65%) patients with SSc- ILD had ≥3 FVC measure-
ments available during the mean 5- year (±2.2) follow- up period, 
allowing for assessment of long- term ILD course. Baseline char-
acteristics did not differ between patients with ≥3 and patients 
with <3 FVC measurements (n=291 (35%)).
To assess the overall disease course, we assessed FVC changes 
between baseline and last available FVC. We found that 49 
(9%) showed major FVC decline (FVC decline of >20%); 75 
(14%) had significant decline (FVC decline 10% to 20%); 76 
(14%) had moderate decline (FVC decline 5% to 10%); 206 
(39%) were stable (FVC changes <5%); and 129 (24%) expe-
rienced improvement in FVC (FVC improvement >5%) over 
the overall disease course (mean 5- year follow- up) (figure 1A). 
The prevalence of significant ILD progression was between 
13% and 18% and the prevalence of moderate progression was 
between 9% and 10% in each 12- month period over this 5- year 
follow- up (figure 1B). These progressive periods rarely appeared 
in consecutive 12- month periods, and progressive periods were 
mostly followed by stable periods (figure 2A). Stable periods 
were followed by a progressive period in about 30% of cases 
(figure 2B). Irrespective of the severity of overall FVC decline 
(major, significant or moderate), most patients still experi-
enced at least one 12- month period of stable or improving FVC 
(table 2). On the other hand, patients with stable or improved 
overall FVC could still experience 12- month periods of FVC 
decline; these declines were more frequently moderate (FVC 
decline 5% to 10%) than significant (FVC decline 10% to 20%). 
Only 178 (33%) patients experienced no period of FVC decline 
of ≥5% during any 12- month period (table 2).
Most patients with SSc- ILD with an overall FVC decline 
over 5 years had a slow pattern of lung function decline, with 
more periods of stability/improvement than decline (58%); 34% 
showed a progressive pattern, with more periods of decline 
than stability/improvement and slow progression. Only 16 (8%) 
Table 2 Number of patients (n (%)) with SSc- ILD in the EUSTAR database with 12- month periods of FVC decline, stratified by overall FVC decline 
from first to last available FVC measurement
Overall FVC change from baseline to last FVC
One 12- month period with FVC 
decline Two or more 12- month periods with FVC decline
No decline 
(n=178)
Moderate 
decline (n=113)
Significant 
decline (n=107)
Only moderate 
declines (n=65)
One significant 
and ≥1 moderate 
decline (n=25)
Only 
significant 
declines 
(n=47)
Improved (n=129) 79 (44) 22 (20) 21 (20) 1 (2) 3 (12) 3 (6)
Stable (n=206) 99 (56) 59 (53) 29 (27) 13 (20) 1 (4) 5 (11)
Moderate decline (n=76) 28 (25) 17 (16) 25 (39) 1 (4) 5 (11)
Significant decline (n=75) 2 (2) 29 (27) 23 (35) 10 (40) 11 (23)
Major decline (n=49) 2 (2) 11 (10) 3 (5) 10 (40) 23 (49)
Overall FVC change from baseline to last FVC: major decline (FVC decline of >20%); significant decline (FVC decline of >10 and ≤20%); moderate decline (FVC decline of 5% to 
10%); stable (FVC decline or improvement of <5%); and improvement (FVC improvement of ≥5%).
EUSTAR, European Scleroderma Trials And Research; FVC, forced vital capacity; SSc- ILD, systemic sclerosis- associated interstitial lung disease.
Figure 3 Patterns of disease course in SSc- ILD. Overall disease course was evaluated by determining the magnitude of FVC changes (% predicted) 
in individual patients from baseline to the end of follow- up defined as follows: major decline (FVC decline of >20%); significant decline (FVC decline 
of 10% to 20%); moderate decline (FVC decline of 5% to 10%); stable (FVC decline or improvement of <5%); and improvement (FVC improvement of 
≥5%). Patterns of disease progression are shown in patients with improved FVC, stable FVC and those with significant or major decline. FVC, forced 
vital capacity; SSc- ILD, systemic sclerosis- associated interstitial lung disease.
copyright.
 on D
ecem
ber 21, 2020 at E
-Library Insel. P
rotected by
http://ard.bm
j.com
/
A
nn R
heum
 D
is: first published as 10.1136/annrheum
dis-2020-217455 on 28 S
eptem
ber 2020. D
ow
nloaded from
 
6 Hoffmann- Vold A- M, et al. Ann Rheum Dis 2020;0:1–9. doi:10.1136/annrheumdis-2020-217455
Systemic sclerosis
patients showed a rapidly declining FVC pattern, with several 
consecutive episodes of FVC decline and no periods of FVC 
stability or improvement. Patterns of progression in patients 
with moderate, significant and major overall decline in FVC%, 
stratified by the presence or absence of a decline in the first 12 
months, are shown in figure 3.
Risk factors predictive of 5-year FVC decline
To identify SSc- ILD patients at risk of ILD progression, we 
assessed the predictive value of baseline clinical variables on FVC 
measurements over the 5- year follow- up period. In multivariable 
linear mixed- effect models, we identified male sex, presence of 
reflux/dysphagia symptoms and high baseline mRSS as the stron-
gest predictors, with significant interaction effects between time 
and these variables. This indicates that FVC changed differently 
over time as a function of one of these predictors (ie, different 
slopes). Older age, higher DLCO, dyspnoea (New York Heart 
Association class 3 or 4) and increased ESR were also signifi-
cantly predictive for FVC decline but without a time interac-
tion effect, indicating that the FVC changed significantly over 
time but not differently between patients with or without these 
clinical features (table 3). Immunosuppressive treatment was not 
predictive for FVC decline over time.
Mortality
Of 826 patients with SSc- ILD, 85 (10%) died during follow- up. 
There were no significant differences in mortality rate between 
patients with significant ILD progression (11 (12%)), moderate 
progression (18 (15%)) or stable ILD (36 (9%)) over the initial 
12±3- month period. In patients with overall FVC changes 
measured between baseline and last available FVC, death 
occurred in 9 of 49 (19%) patients with major decline; 7 of 75 
(9%) patients with significant decline; 12 of 76 patients (16%) 
with moderate decline; 18 of 206 (9%) patients who were stable; 
and 9 of 129 (7%) patients with improvement, with differences 
not statistically significant. As there were only a small number of 
events, no regression analyses were performed.
DISCUSSION
This is the largest study to prospectively analyse the prevalence 
of progressive ILD in patients with SSc- ILD, and the first to 
describe comprehensively the disease course and patterns of ILD 
progression in patients with SSc over the long term.
The proportion of patients with SSc- ILD who experienced 
progressive ILD during the initial 12±3- month period was 27%, 
and in each 12- month period over the mean 5- year follow- up, 
23% to 27% of patients experienced progression. These findings 
are in agreement with estimates of progressive ILD prevalence of 
31% to 32% derived from serial lung function data in patients 
with SSc6 and an international physician survey.40
Here, we show that patterns of FVC are frequently incon-
sistent between consecutive 12- month periods. Most patients 
who experienced an overall decline in FVC had periods of 
FVC improvement and, conversely, some patients whose FVC 
improved overall had periods of FVC decline. Patients with 
overall major FVC decline (FVC decline >20% over the entire 
study period) usually had several 12- month periods with FVC 
decline >10% rather than FVC decline of 5% to 10%. Others 
experienced a slower, but cumulative course of declining FVC. 
Such patients with slower progression can easily be overlooked 
in clinical practice and in current treatment strategies that target 
patients who progress rapidly and with significant FVC changes. 
Smaller changes in FVC (5% to 10%) may in themselves be clin-
ically significant, as seen in patients with idiopathic pulmonary 
fibrosis.41 42 In clinical practice, this means that FVC decline 
>5% should alert physicians, especially when multiple declines 
occur, even when not in consecutive periods. These results high-
light a pitfall in current clinical practice, where treatment is often 
initiated after FVC decline has happened, and thus when lung 
damage has already occurred.24 Novel treatment concepts are 
needed and should aim for prevention of progression to avoid 
irreversible organ damage. These results also stress and highlight 
the need for close monitoring of all patients with SSc- ILD, as also 
recently suggested by the European expert consensus.43 Respira-
tory symptoms, changes in HRCT findings and desaturation on 
Table 3 Risk factors for change in FVC over the 5- year follow- up in patients with ≥3 serial FVC measurements in univariable and multivariable 
linear mixed- effect regression analysis
Predictor variable
Univariable Multivariable
Coefficient 95% CI P value Coefficient 95% CI P value
Time −0.45 −0.72 to −1.7 0.002 0.8 0.22 to 1.39 0.007
Reflux/dysphagia symptoms −2.06 −5.06 to 0.94 0.180 0.58 –2.18 to 3.34 0.681
Time×reflux/dysphagia symptoms −0.76 −1.34 to −0.17 0.011 −0.72 −1.34 to −0.10 0.024
mRSS −0.51 −0.69 to −0.33 <0.001 –0.31 –0.47 to –0.15 <0.001
Time×mRSS −0.05 −0.07 to −0.01 0.011 −0.06 −0.10 to −0.02 0.002
Sex −5.25 −8.91 to −1.59 0.005 –3.90 –7.29 to –0.53 0.024
Time×sex −0.97 −1.72 to −0.21 0.012 −1.30 −2.10 to −0.49 0.002
Age 0.42 0.31 to 1.53 <0.001 0.47 0.37 to 0.57 <0.001
DLCO 0.55 0.47 to 0.62 <0.001 0.45 0.37 to 0.52 <0.001
ESR −0.14 −0.21 to −0.01 0.001 −0.09 −0.15 to −0.03 0.005
NYHA class −14.59 −18.7 to −10.49 <0.001 −4.76 −6.59 to −2.92 <0.001
ACA 11.42 7.65 to 15.19 <0.001
ARA 10.95 1.62 to 20.27 0.021
ATA −5.01 −7.98 to −2.05 0.001
CRP −7.72 −11.01 to −4.43 <0.001
dcSSc −6.37 −7.43 to −3.32 <0.001
ACA, anti- centromere antibody; ARA, anti- RNA polymerase III antibody; ATA, anti- topoisomerase I antibody; CRP, C- reactive protein; dcSSc, diffuse cutaneous systemic sclerosis; 
DLCO, diffusion capacity of the lungs for carbon monoxide; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; mRSS, modified Rodnan skin score; NYHA, New York 
Heart Association.
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exercise tests should all be implemented in clinical practice to 
assess ILD progression and aid treatment decisions.
Robust predictive risk factors are very important for the early 
identification of progressive patients. Our large, multicentre 
study demonstrates that skin fibrosis (higher mRSS), male sex 
and the presence of reflux/dysphagia symptoms are the stron-
gest predictors for FVC decline over time. Other predictive 
parameters included the presence of inflammation (higher ESR) 
and shorter disease duration, which are already frequently used 
as enrichment strategies for clinical studies. These parameters 
may also be applied in daily clinical practice, helping to iden-
tify patients who should receive treatment early, even before the 
first FVC decline has occurred. However, if earlier treatment of 
patients at risk for FVC decline truly leads to better outcomes, it 
needs to be analysed in appropriate randomised controlled clin-
ical trials in the future. Risk factors identified in this study are 
potential inclusion criteria for such a trial. Interestingly, contrary 
to our finding that higher FVC at baseline was predictive for 
ILD progression, previous studies suggested that lower FVC at 
baseline is a risk factor for progressive ILD.16 20 These studies 
included some SSc patients without ILD, and one study assessed 
patients within 3 years of SSc diagnosis. Furthermore, defini-
tions of progression (FVC decline of ≥15%,20 FVC or DLCO 
decline of ≥15%, or FVC or DLCO falling below 55%
16) differed 
from those in our study. The strongest association with further 
FVC decline was seen in patients with baseline FVC <65% 
predicted,16 lower than the mean value in our study (86%). Our 
contrasting findings may reflect these differences and should be 
assessed in other unselected cohorts.
Strengths of our study include the use of a large set of prospec-
tive, representative real- world data, which increases the applica-
bility of our results to clinical practice and different definitions 
of ILD progression. Nonetheless, this study has several limita-
tions. While the data were gathered prospectively, this was a post 
hoc analysis. No central lung function reading was conducted, 
increasing the variability of FVC and DLCO. Most patients with 
SSc- ILD in the database (1433/2259) did not have serial lung 
function data. Data on immunosuppressant use were only avail-
able for 244/826 eligible patients, and the exact date of initia-
tion, treatment indication and cumulative doses are unknown. 
Several studies7 8 15 have suggested that the extent of lung fibrosis 
by HRCT is prognostic for disease progression and mortality 
in SSc- ILD. Although data regarding the extent of lung fibrosis 
were not available in the database for the present analysis, they 
may be a valuable addition in future studies. Recent analyses also 
suggest that mRSS progression is an important risk factor for 
later FVC progression,39 which was not analysed in this study. 
A lead time bias cannot be excluded, as this was not an incident 
cohort. Finally, ILD- specific mortality was not available in the 
EUSTAR database. Here, all- cause mortality was not influenced 
by ILD progression; as recently highlighted,5 it is likely that ILD- 
specific mortality differs between progressive and stable ILD 
patients.
CONCLUSION
This study provides novel insights into the occurrence of 
progressive ILD in SSc- ILD. The results stress the heterogeneity 
and variability of the course of ILD in SSc. Close monitoring of 
patients with SSc- ILD and awareness of the variable course of 
progression is of high importance in considering when to initiate 
treatment.
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